Liam Killingstad

Liam Killingstad, co-founder of KHORA Therapeutics and Operating Partner at Finiam Investments, dives into the transformative role of family offices in biotech. He shares how personal experiences with rare cancers ignited a mission-driven investment approach. The conversation uncovers the unique strategies family offices employ, their agile funding capabilities, and the impact of tailored investments on biotech innovation. Liam also reflects on his journey from investment banking to biotech, highlighting the essential skills required to bridge these industries effectively.